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ABSTRACT
Cell line identification is emerging as an essential
method for every cell line user in research commu-
nity to avoid using misidentified cell lines for experi-
ments and publications. IGRhCellID (http://igrcid
.ibms.sinica.edu.tw) is designed to integrate eight
cell identification methods including seven
methods (STR profile, gender, immunotypes, karyo-
type, isoenzyme profile, TP53 mutation and muta-
tions of cancer genes) available in various public
databases and our method of profiling genome al-
terations of human cell lines. With data validation of
11 small deleted genes in human cancer cell lines,
profiles of genomic alterations further allow users to
search for human cell lines with deleted gene to
serve as indigenous knock-out cell model (such as
SMAD4 in gene view), with amplified gene to be the
cell models for testing therapeutic efficacy (such as
ERBB2 in gene view) and with overlapped aberrant
chromosomal loci for revealing common cancer
genes (such as 9p21.3 homozygous deletion with
co-deleted CDKN2A, CDKN2B and MTAP in
chromosome view). IGRhCellID provides not only
available methods for cell identification to help
eradicating concerns of using misidentified cells
but also designated genetic features of human cell
lines for experiments.
INTRODUCTION
Cell lines are important and essential reagents for almost
every experiment in biomedical research. Because of indef-
inite growing capability and extensive use in research
community, cell lines are frequently contaminated and
misidentiﬁed in literatures (1–3). It has been recommended
that researchers should provide authenticities of their ex-
perimental cell lines before publications (4–6).
The problem of using misidentiﬁed cell lines in pub-
lished literatures has been recognized for several
decades. It has been reported by international cell
repositories that the incidence of cell line misidentiﬁcation
has been estimated in between 16% and 36% based on
analysis of submitted cell lines (4). The most notorious
example is the false description of HeLa cervical cancer
cell line to several different origins and cell types including
Chang liver as ‘normal liver cell’, KB as ‘oral cancer cell’,
HEp-2 as ‘laryngeal cancer cell’, Int-407 as ‘non-
transformed intestinal epithelial cell’ and so on (7–9).
The consequences of using misidentiﬁed and
contaminated cell lines not only generate erroneous and
misleading results but also waste research funding and
delay scientiﬁc progression. Currently, there is a list of
contaminated or misidentiﬁed cell lines released in the
websites of the international cell repositories to avoid
using incorrect cell lines for experiments (5).
For cell identiﬁcation, several methods were developed
to detect cell line contamination or misidentiﬁcation
including isoenzyme analysis, karyotyping, human leuko-
cyte antigen (HLA)-typing, immunotyping, DNA ﬁnger-
printing and short tandem repeat (STR) proﬁling. These
methods can distinguish and match the cell line identity to
the cell line speciﬁc proﬁles, but with various levels of
ambiguity and limitations (4). Among these methods,
STR proﬁling of human cell lines adopted from routing
assays of paternity testing and forensic analysis is
becoming the most recommended method for cell identi-
ﬁcation (4,10). A database, Cell Line Integrated Molecular
Authentication (CLIMA), collecting the STR proﬁling of
human cell lines is currently available for scientiﬁc
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STR proﬁling in its application for cell identiﬁcation.
First of all, the major limitation for STR proﬁling is its
capability to detect cell contamination from other species
because PCR primers of STR markers for authenticity
were designed based on human sequence. Second, since
majority of cell lines were established from malignant
tissues, the gain and loss of cancer genomes increase the
ambiguity and reduce the power to match a speciﬁc STR
proﬁle. Third, STR proﬁling is unable to distinguish
sub-lines derived from the same cell line due to identical
STR alleles. Finally, STR proﬁling requires commercial
reagents, expensive instruments and genotyping software
for data interpretation. Unless the cost of genotyping can
be dramatically reduced and the genotyping experiments
can be accessed in nearby core facility, using current
methods including STR proﬁling for routing cell identiﬁ-
cation might not be able to ease the persistent problem of
cell misidentiﬁcation in our research community.
Since the efforts to eradicate the misidentiﬁcation
problem is unsuccessful, IGRhCellID is established to
provide not only STR proﬁles of human cell lines as the
most recommended assay for cell authenticity but also
other authentic tools with conventional laboratory PCR
or DNA sequencing assays for routing examination of
proper cell identiﬁcation. In addition, IGRhCellID can
also allow researchers to search the available cell lines
with designated genetic features and to identify common
altered loci and genes overlapped in multiple cell lines.
DATABASE CONSTRUCTION
IGRhCellID database contains integrated genomic infor-
mation of 520 human cell lines annotated with eight dif-
ferent methods for cell identiﬁcation. The conventional
methods including cell line information of STR proﬁle,
gender, immunotypes, karyotype and isoenzyme proﬁle
were downloaded from common international cell
repositories including ATCC, DSMZ, JCRB, ECACC
and RIKEN BioResource Center. In addition, we
provided cell line information of TP53 mutation data
from UMD TP53 mutation database (12,13), somatic
mutation data from Catalogue of Somatic Mutations in
Cancer (COSMIC) database (14) and genome-wide
amplicon and homozygous deletion (HD) proﬁle from
our laboratory. We recently established a comprehensive
protocol to analyze copy number alterations (CNA) in
cancer genomes using high density single nucleotide poly-
morphism (SNP) arrays with non-paired reference
genomes (15). Based on our protocol, we were able to
validate known and identify novel amplicons and HDs
in 23 cancer cell lines and further identify novel cancer
genes in hepatocellular carcinomas.
For annotation of genome-wide amplicons and HDs in
human cell lines, we downloaded 520 independent
genotyping data of Affymetrix 250K, 500K and 6.0
(1800K) SNP GeneChip array sets of human cell lines
from Array Data Management System at National
Cancer Institute of USA (caArray, 338 cancer cell lines)
(16), Gene Expression Omnibus database (GEO, 182 cell
lines) (17) and International HapMap project as normal
reference control data. By using dChip analysis software
(18), we smoothed each SNP data intensity by three con-
tinuous SNPs to create an inferred copy number (ICN) for
each SNP and deﬁned amplicons and HDs in greater than
3 and less than 0.5 ICN, respectively. Together, we
identiﬁed a total of 13840927 ampliﬁed SNPs and
182343 loss SNPs located in amplicons and HDs,
respectively in 520 human cell lines. To check our
analysis protocol and data quality, we examined 11
known genes (LRP1B, FHIT, PARK2, PTPRD,
CDKN2B, CDKN2A, PTEN, WWOX, CREBBP, TP53
and SMAD4) with reported small deletions in published
literatures for validation (19–29). In 49 previously
reported deletion events of above 11 genes in cancer cell
lines, we have 96% (47/49) validation rate (Supplementary
Table S1). Furthermore, we downloaded and integrated
950 microarray gene expression data sets of the 358 cell
lines from caArray to show the concordance of altered
gene expression with the corresponding aberrant
amplicons and HD regions.
RESULTS
Cell identiﬁcation
Cell lines can be selected by quick search, by searching the
name in alphabetic order or by searching the categories of
cell line origin based on body location/systems in National
Cancer Institute. After selecting a cell line in cell line view,
in addition to common STR proﬁling and other conven-
tional methods, users can search its genome-wide altered
SNPs in amplicons and HDs along the physical and cyto-
genetic locations of chromosomes (Figure 1). In genomic
alteration proﬁle of a selected cell line, user can continu-
ously click on the alteration (green lines strand for HD
and red lines strand for ampliﬁcation) and retrieve SNPs
for cell identiﬁcation with multiple PCR or quantitative
PCR reactions. Furthermore, the existence of somatic mu-
tations in TP53 (UMD TP53 database) or other cancer
genes (COSMIC) can provide additional support for
authenticity.
Altered genes and loci in cell lines
The proﬁles of genome-wide amplicons and HDs not only
provide a new authentic method of a cell line but also
allow for selection of a designated cell line with requested
genetic features (in gene or intergenic view). Moreover,
common somatic alterations shared in multiple cell lines
across cancer types can be displayed in chromosome view.
For instance, after selection of cell lines in gene view, users
can search a gene and align its genetic alterations in one or
multiple cell lines. By using quick examples provided in
IGRhCellID, users can ﬁnd that SMAD4 a tumor sup-
pressor gene in pancreatic carcinoma is deleted in FaDu
(a pharynx squamous carcinoma cell line), COLO 201
(colorectal adenocarcinoma cell line) and SW 1573 (lung
alveolar carcinoma cell line) with concordance of down
regulation in gene expression. Only SMAD4 HD in
FaDu was reported before but not COLO 201 and SW
1573 cells (19). The integrated information will provide the
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knock-out model for biological studies.
In intergenic view, after selection of cell lines, users can
zoom out the aberrant amplicon or HD region to examine
the boundary of aberrant locus and its affected neighbor-
ing genes. For instance, ERBB2 also called HER2 or NEU
is a known oncogene in human breast cancer. When
search ERBB2 in 26 breast cancer cell lines, users can
observe only 20% (6/26) cell lines with ampliﬁcation in
the region. After selecting six ampliﬁed cell lines and
zoom out to a 1Mb region surrounding ERBB2, users
will observe boundaries in some breast cell lines including
a smallest amplicon in HCC2218 cells containing eight
genes and the largest amplicon in UACC-812 cells
containing 29 genes. The ampliﬁcation of oncogenic
ERBB2 in these cell lines will provide not only positive
control cell lines for ERBB2 expression but also natural
cell models for studying the therapeutic efﬁcacy of drugs
against ERBB2 over-expression in breast cancer cells.
In chromosome view, IGRhCellID also allows users to
search a cytogenetic region with overlapped somatic alter-
ations in selected human cell lines across cancer types in
detail resolution to gene and SNP levels. As indicated in
our tutorial example, aberrant chromosome nine in six cell
lines classiﬁed in endocrine system (ﬁve thyroid carcinoma
and one adrenal gland carcinoma cell lines) were selected
and aligned in chromosome view. Apparently, one
overlapped HD region on 9p21.3 was detected in three
Figure 1. A tutorial example to ﬁnd homozygous deleted SNPs in a cell line. In step 1, users can select a cell line by the name in quick search, in
alphabetic order or in categories based on NCI cancers by body location/systems. By clicking A549 as an example, in step 2, users will retrieve the
proﬁle of genome-wide amplicons and HDs (chromosome 1 as an example) along with the available authentic tools for A549. In step 3, by clicking
the HD on chromosome 1p35.2 as an example, the detail localizations of HD and genes are presented. In step 4, users can further click on the HD to
display the raw data. In step 5, the genes and SNPs located in HD are presented. By moving curser to the ‘No. of SNP’ or ‘gene in this region’, user
can observe the SNPs and genes residing in this HD, respectively. These SNPs will allow users to retrieve primers information in NCBI dbSNP for
authentic experimental designs.
D522 Nucleic AcidsResearch, 2011, Vol.39, Database issuecell lines. After clicking on the chromosome to enlarge the
view, three known genes CDKN2A, CDKN2B and MTAP
were co-deleted in the HD region.
DISCUSSION
In addition to providing information of STR proﬁles
of 520 human cell lines, IGRhCellID integrated other
authentic tools and genomic alterations for helping re-
searchers to validate their experimental cell lines using
conventional methods, to select suitable cell lines with
proper genetic background for their experimental
designs and to support the long standing efforts for
eradicating the concerns of using misidentiﬁed cell lines.
Using authentic tools to maintain correct cell identiﬁca-
tion is even more critical in ﬁelds of establishing and using
stem cell lines for therapeutic applications. Although in-
tegration of available authentic tools and proﬁles of
genomic alterations of human cell lines in IGRhCellID
provides convenient and accessible methods for cell iden-
tiﬁcation, additional efforts to apply statistic analysis for
obtaining the discrimination power of cell authenticity
using either one or combined authentic methods should
be studied. Nevertheless, IGRhCellID will continue to
collect available authentic data for all available cell lines
derived from human and other species. Our efforts should
help resolving the crisis of using misidentiﬁcation cell lines
and improve the selection of proper cell lines for
designated experiments.
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Supplementary Data are available at NAR Online.
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